Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

详细信息    查看全文

• 作者：Monica Cabrero¹ ; Alejandro Martin¹ ; ^{amartingar@usal.es} ; Javier Briones² ; Jorge Gayoso³ ; Isidro Jarque⁴ ; Javier L&oacute ; pez⁵ ; Carlos Grande⁶ ; Inmaculada Heras⁷ ; Reyes Arranz⁸ ; Teresa Bernal⁹ ; Estefania Perez-Lopez¹ ; Oriana L&oacute ; pez-Godino⁷ ; Eulogio Conde¹⁰ ; Dolores Caballero¹
• 关键词：Allogeneic transplantation ; Reduced-intensity conditioning ; Radioimmunotherapy ; B cell lymphoma ; Clinical trial
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：23
• 期：1
• 页码：53-59
• 全文大小：784 K
• 卷排序：23

文摘

Y-90 ibritumomab tiuxetan was used as a part of a reduced-intensity conditioning regimen phase II multicenter trial Conditioning regimen with radioimmunotherapy is safe and well tolerated The addition of radioimmunotherapy results in a long-term progression-free survival of 44% No significant toxicities related to Y-90 ibritumomab tiuxetan have been reported Our 46-month median follow-up is the longest reported in a radioimmunotherapy allogeneic stem cell transplantation trial